Introduction: Hereditary angioedema (HAE) is a rare and potentially life-threatening condition caused by deficiency or dysfunction of C1 inhibitor and accompanied by recurrent episodes of swelling affecting different parts of body. Patients experience significant morbidity and have impaired quality of life. Mortality may result from laryngeal attacks and asphyxiation. In last five years, developments in HAE therapies have changed HAE treatment paradigm.Areas covered: In United States and Europe, icatibant, a BR2 bradykinin receptor antagonist, is approved for self administration to treat acute attacks of HAE. It appears to have a favorable efficacy and safety profile. We examine pharmacokinetic profile, published data on safety and efficacy, important drug trials and post marketing surveillance studies of icatibant.Expert opinion: Icatibant has the desirable characteristics for self-administration such as safety, portability, accessibility, stability at room temperature and ease of administration. It is the only treatment approved for self-administration by subcutaneous route. Access to effective and safe treatment will improve quality of life, reduce morbidity and alleviate economic burden of the disease by reduced disability and number of emergency visits related to HAE attacks.
All Science Journal Classification (ASJC) codes
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
- Health Policy
- Pharmacology (medical)